nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—UGT1A9—Mycophenolic acid—psoriasis	0.0625	0.0996	CbGbCtD
Sorafenib—UGT1A1—Mycophenolic acid—psoriasis	0.0511	0.0815	CbGbCtD
Sorafenib—UGT1A9—Mycophenolate mofetil—psoriasis	0.0349	0.0556	CbGbCtD
Sorafenib—UGT1A1—Mycophenolate mofetil—psoriasis	0.0286	0.0455	CbGbCtD
Sorafenib—CYP2C8—Tazarotene—psoriasis	0.0226	0.036	CbGbCtD
Sorafenib—CYP3A5—Beclomethasone—psoriasis	0.0219	0.0348	CbGbCtD
Sorafenib—CYP1A2—Clobetasol propionate—psoriasis	0.0215	0.0342	CbGbCtD
Sorafenib—ABCC2—Mycophenolate mofetil—psoriasis	0.0174	0.0277	CbGbCtD
Sorafenib—ABCG2—Mycophenolate mofetil—psoriasis	0.0157	0.025	CbGbCtD
Sorafenib—ABCC2—Cyclosporine—psoriasis	0.0132	0.021	CbGbCtD
Sorafenib—CYP2B6—Cholecalciferol—psoriasis	0.0128	0.0203	CbGbCtD
Sorafenib—ABCG2—Hydrocortisone—psoriasis	0.0126	0.0201	CbGbCtD
Sorafenib—ABCG2—Cyclosporine—psoriasis	0.0119	0.019	CbGbCtD
Sorafenib—ABCC4—Methotrexate—psoriasis	0.0117	0.0187	CbGbCtD
Sorafenib—CYP1A2—Methoxsalen—psoriasis	0.0113	0.018	CbGbCtD
Sorafenib—CYP2D6—Hydroxyurea—psoriasis	0.0102	0.0162	CbGbCtD
Sorafenib—CYP2C8—Cholecalciferol—psoriasis	0.00966	0.0154	CbGbCtD
Sorafenib—CYP3A7—Hydrocortisone—psoriasis	0.00932	0.0148	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.00932	0.0148	CbGbCtD
Sorafenib—CYP3A7—Cyclosporine—psoriasis	0.0088	0.014	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0088	0.014	CbGbCtD
Sorafenib—CYP3A5—Mycophenolate mofetil—psoriasis	0.00871	0.0139	CbGbCtD
Sorafenib—ABCC2—Dexamethasone—psoriasis	0.00868	0.0138	CbGbCtD
Sorafenib—CYP2C8—Mycophenolate mofetil—psoriasis	0.00837	0.0133	CbGbCtD
Sorafenib—CYP2C19—Cholecalciferol—psoriasis	0.0081	0.0129	CbGbCtD
Sorafenib—ABCG2—Dexamethasone—psoriasis	0.00784	0.0125	CbGbCtD
Sorafenib—CYP3A4—Calcitriol—psoriasis	0.0076	0.0121	CbGbCtD
Sorafenib—CYP3A5—Hydrocortisone—psoriasis	0.00699	0.0111	CbGbCtD
Sorafenib—ABCC2—Methotrexate—psoriasis	0.00697	0.0111	CbGbCtD
Sorafenib—CYP2C9—Cholecalciferol—psoriasis	0.00674	0.0107	CbGbCtD
Sorafenib—CYP2C8—Hydrocortisone—psoriasis	0.00672	0.0107	CbGbCtD
Sorafenib—CYP3A5—Cyclosporine—psoriasis	0.0066	0.0105	CbGbCtD
Sorafenib—CYP2C8—Cyclosporine—psoriasis	0.00635	0.0101	CbGbCtD
Sorafenib—ABCG2—Methotrexate—psoriasis	0.0063	0.01	CbGbCtD
Sorafenib—CYP2D6—Cholecalciferol—psoriasis	0.00616	0.00981	CbGbCtD
Sorafenib—CYP3A4—Methoxsalen—psoriasis	0.00591	0.00942	CbGbCtD
Sorafenib—CYP3A7—Dexamethasone—psoriasis	0.00579	0.00923	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.00579	0.00923	CbGbCtD
Sorafenib—ABCB1—Mycophenolate mofetil—psoriasis	0.00567	0.00903	CbGbCtD
Sorafenib—CYP2C19—Prednisone—psoriasis	0.00562	0.00894	CbGbCtD
Sorafenib—CYP2B6—Dexamethasone—psoriasis	0.00552	0.00879	CbGbCtD
Sorafenib—CYP2C19—Cyclosporine—psoriasis	0.00532	0.00848	CbGbCtD
Sorafenib—ABCB1—Betamethasone—psoriasis	0.00486	0.00774	CbGbCtD
Sorafenib—ABCB1—Prednisolone—psoriasis	0.0048	0.00764	CbGbCtD
Sorafenib—ABCB1—Hydrocortisone—psoriasis	0.00455	0.00724	CbGbCtD
Sorafenib—ABCB1—Prednisone—psoriasis	0.00453	0.00722	CbGbCtD
Sorafenib—CYP2C9—Cyclosporine—psoriasis	0.00443	0.00705	CbGbCtD
Sorafenib—CYP3A5—Dexamethasone—psoriasis	0.00435	0.00692	CbGbCtD
Sorafenib—ABCB1—Cyclosporine—psoriasis	0.0043	0.00684	CbGbCtD
Sorafenib—CYP2C8—Dexamethasone—psoriasis	0.00418	0.00666	CbGbCtD
Sorafenib—CYP2D6—Cyclosporine—psoriasis	0.00405	0.00645	CbGbCtD
Sorafenib—CYP3A4—Cholecalciferol—psoriasis	0.00392	0.00624	CbGbCtD
Sorafenib—CYP2C19—Dexamethasone—psoriasis	0.00351	0.00558	CbGbCtD
Sorafenib—CYP3A4—Triamcinolone—psoriasis	0.0034	0.00541	CbGbCtD
Sorafenib—CYP3A4—Mycophenolate mofetil—psoriasis	0.0034	0.00541	CbGbCtD
Sorafenib—CDK7—Mycophenolic acid—Mycophenolate mofetil—psoriasis	0.00328	1	CbGdCrCtD
Sorafenib—TIE1—endothelium—psoriasis	0.00294	0.0837	CbGeAlD
Sorafenib—CYP2C9—Dexamethasone—psoriasis	0.00291	0.00464	CbGbCtD
Sorafenib—CYP3A4—Betamethasone—psoriasis	0.00291	0.00464	CbGbCtD
Sorafenib—CYP3A4—Prednisolone—psoriasis	0.00287	0.00458	CbGbCtD
Sorafenib—ABCB1—Dexamethasone—psoriasis	0.00283	0.0045	CbGbCtD
Sorafenib—MUSK—tendon—psoriasis	0.00282	0.0803	CbGeAlD
Sorafenib—CYP3A4—Hydrocortisone—psoriasis	0.00273	0.00434	CbGbCtD
Sorafenib—CYP3A4—Prednisone—psoriasis	0.00271	0.00432	CbGbCtD
Sorafenib—CYP2D6—Dexamethasone—psoriasis	0.00267	0.00424	CbGbCtD
Sorafenib—CYP3A4—Cyclosporine—psoriasis	0.00257	0.0041	CbGbCtD
Sorafenib—FLT4—endothelium—psoriasis	0.00243	0.0691	CbGeAlD
Sorafenib—ABCB1—Methotrexate—psoriasis	0.00227	0.00362	CbGbCtD
Sorafenib—KIT—skin epidermis—psoriasis	0.00195	0.0555	CbGeAlD
Sorafenib—FLT1—endothelium—psoriasis	0.00189	0.0538	CbGeAlD
Sorafenib—CYP3A4—Dexamethasone—psoriasis	0.00169	0.0027	CbGbCtD
Sorafenib—KDR—endothelium—psoriasis	0.0016	0.0454	CbGeAlD
Sorafenib—KIT—endothelium—psoriasis	0.00142	0.0403	CbGeAlD
Sorafenib—TAOK2—tendon—psoriasis	0.0012	0.0341	CbGeAlD
Sorafenib—AURKC—tendon—psoriasis	0.00119	0.0339	CbGeAlD
Sorafenib—ZAK—tendon—psoriasis	0.00104	0.0297	CbGeAlD
Sorafenib—HIPK3—tendon—psoriasis	0.00102	0.0291	CbGeAlD
Sorafenib—BRAF—tendon—psoriasis	0.000916	0.0261	CbGeAlD
Sorafenib—EPHX2—tendon—psoriasis	0.000876	0.0249	CbGeAlD
Sorafenib—RAF1—skin of body—psoriasis	0.000802	0.0228	CbGeAlD
Sorafenib—EPHB6—skin of body—psoriasis	0.000797	0.0227	CbGeAlD
Sorafenib—FGFR1—tendon—psoriasis	0.000779	0.0222	CbGeAlD
Sorafenib—MAP3K7—tendon—psoriasis	0.000738	0.021	CbGeAlD
Sorafenib—MKNK2—tendon—psoriasis	0.000715	0.0203	CbGeAlD
Sorafenib—RET—tendon—psoriasis	0.000697	0.0198	CbGeAlD
Sorafenib—CSF1R—skin of body—psoriasis	0.000665	0.0189	CbGeAlD
Sorafenib—RALBP1—tendon—psoriasis	0.000646	0.0184	CbGeAlD
Sorafenib—FLT1—tendon—psoriasis	0.000614	0.0175	CbGeAlD
Sorafenib—RAF1—tendon—psoriasis	0.00061	0.0174	CbGeAlD
Sorafenib—EPHB6—tendon—psoriasis	0.000607	0.0173	CbGeAlD
Sorafenib—KIT—skin of body—psoriasis	0.000604	0.0172	CbGeAlD
Sorafenib—PDGFRB—skin of body—psoriasis	0.00059	0.0168	CbGeAlD
Sorafenib—STK10—tendon—psoriasis	0.000581	0.0165	CbGeAlD
Sorafenib—PDGFRA—tendon—psoriasis	0.000575	0.0164	CbGeAlD
Sorafenib—MAP2K5—tendon—psoriasis	0.000519	0.0148	CbGeAlD
Sorafenib—KDR—tendon—psoriasis	0.000519	0.0148	CbGeAlD
Sorafenib—CSF1R—tendon—psoriasis	0.000507	0.0144	CbGeAlD
Sorafenib—HTR2B—skin of body—psoriasis	0.000467	0.0133	CbGeAlD
Sorafenib—PDGFRB—tendon—psoriasis	0.000449	0.0128	CbGeAlD
Sorafenib—ABCC4—tendon—psoriasis	0.000358	0.0102	CbGeAlD
Sorafenib—HTR2B—tendon—psoriasis	0.000356	0.0101	CbGeAlD
Sorafenib—ABCC2—tendon—psoriasis	0.000346	0.00985	CbGeAlD
Sorafenib—CYP2B6—skin of body—psoriasis	0.000306	0.00871	CbGeAlD
Sorafenib—Infestation NOS—Methotrexate—psoriasis	8.38e-05	0.000437	CcSEcCtD
Sorafenib—Infestation—Methotrexate—psoriasis	8.38e-05	0.000437	CcSEcCtD
Sorafenib—Flushing—Prednisone—psoriasis	8.36e-05	0.000435	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Cyclosporine—psoriasis	8.35e-05	0.000435	CcSEcCtD
Sorafenib—Skin disorder—Hydrocortisone—psoriasis	8.35e-05	0.000435	CcSEcCtD
Sorafenib—Fatigue—Cyclosporine—psoriasis	8.34e-05	0.000435	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Methotrexate—psoriasis	8.31e-05	0.000433	CcSEcCtD
Sorafenib—Dyspepsia—Mycophenolate mofetil—psoriasis	8.31e-05	0.000433	CcSEcCtD
Sorafenib—Pain—Cyclosporine—psoriasis	8.27e-05	0.000431	CcSEcCtD
Sorafenib—Constipation—Cyclosporine—psoriasis	8.27e-05	0.000431	CcSEcCtD
Sorafenib—Dry mouth—Triamcinolone—psoriasis	8.26e-05	0.00043	CcSEcCtD
Sorafenib—Renal failure—Methotrexate—psoriasis	8.24e-05	0.000429	CcSEcCtD
Sorafenib—Angioedema—Betamethasone—psoriasis	8.22e-05	0.000429	CcSEcCtD
Sorafenib—Angioedema—Dexamethasone—psoriasis	8.22e-05	0.000429	CcSEcCtD
Sorafenib—Decreased appetite—Mycophenolate mofetil—psoriasis	8.2e-05	0.000428	CcSEcCtD
Sorafenib—Anorexia—Hydrocortisone—psoriasis	8.2e-05	0.000427	CcSEcCtD
Sorafenib—Diarrhoea—Mycophenolic acid—psoriasis	8.18e-05	0.000426	CcSEcCtD
Sorafenib—Stomatitis—Methotrexate—psoriasis	8.17e-05	0.000426	CcSEcCtD
Sorafenib—Angiopathy—Prednisone—psoriasis	8.17e-05	0.000426	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	8.15e-05	0.000425	CcSEcCtD
Sorafenib—Immune system disorder—Prednisone—psoriasis	8.13e-05	0.000424	CcSEcCtD
Sorafenib—Anaphylactic shock—Triamcinolone—psoriasis	8.1e-05	0.000422	CcSEcCtD
Sorafenib—Syncope—Betamethasone—psoriasis	8.07e-05	0.000421	CcSEcCtD
Sorafenib—Syncope—Dexamethasone—psoriasis	8.07e-05	0.000421	CcSEcCtD
Sorafenib—Pain—Mycophenolate mofetil—psoriasis	8.07e-05	0.000421	CcSEcCtD
Sorafenib—Constipation—Mycophenolate mofetil—psoriasis	8.07e-05	0.000421	CcSEcCtD
Sorafenib—Arrhythmia—Prednisone—psoriasis	8.04e-05	0.000419	CcSEcCtD
Sorafenib—Infection—Triamcinolone—psoriasis	8.04e-05	0.000419	CcSEcCtD
Sorafenib—Shock—Triamcinolone—psoriasis	7.96e-05	0.000415	CcSEcCtD
Sorafenib—Alopecia—Prednisone—psoriasis	7.96e-05	0.000415	CcSEcCtD
Sorafenib—Hepatobiliary disease—Methotrexate—psoriasis	7.93e-05	0.000413	CcSEcCtD
Sorafenib—Gastrointestinal pain—Cyclosporine—psoriasis	7.91e-05	0.000412	CcSEcCtD
Sorafenib—Loss of consciousness—Betamethasone—psoriasis	7.91e-05	0.000412	CcSEcCtD
Sorafenib—Loss of consciousness—Dexamethasone—psoriasis	7.91e-05	0.000412	CcSEcCtD
Sorafenib—Dizziness—Mycophenolic acid—psoriasis	7.91e-05	0.000412	CcSEcCtD
Sorafenib—Epistaxis—Methotrexate—psoriasis	7.91e-05	0.000412	CcSEcCtD
Sorafenib—Mental disorder—Prednisone—psoriasis	7.89e-05	0.000411	CcSEcCtD
Sorafenib—Erythema—Prednisone—psoriasis	7.84e-05	0.000408	CcSEcCtD
Sorafenib—Malnutrition—Prednisone—psoriasis	7.84e-05	0.000408	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Hydrocortisone—psoriasis	7.83e-05	0.000408	CcSEcCtD
Sorafenib—Hypertension—Betamethasone—psoriasis	7.77e-05	0.000405	CcSEcCtD
Sorafenib—Hypertension—Dexamethasone—psoriasis	7.77e-05	0.000405	CcSEcCtD
Sorafenib—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	7.72e-05	0.000402	CcSEcCtD
Sorafenib—Urticaria—Cyclosporine—psoriasis	7.69e-05	0.0004	CcSEcCtD
Sorafenib—Myalgia—Betamethasone—psoriasis	7.66e-05	0.000399	CcSEcCtD
Sorafenib—Myalgia—Dexamethasone—psoriasis	7.66e-05	0.000399	CcSEcCtD
Sorafenib—Abdominal pain—Cyclosporine—psoriasis	7.65e-05	0.000399	CcSEcCtD
Sorafenib—Body temperature increased—Cyclosporine—psoriasis	7.65e-05	0.000399	CcSEcCtD
Sorafenib—Vomiting—Mycophenolic acid—psoriasis	7.6e-05	0.000396	CcSEcCtD
Sorafenib—Dyspepsia—Hydrocortisone—psoriasis	7.57e-05	0.000394	CcSEcCtD
Sorafenib—Haemoglobin—Methotrexate—psoriasis	7.56e-05	0.000394	CcSEcCtD
Sorafenib—Rash—Mycophenolic acid—psoriasis	7.54e-05	0.000393	CcSEcCtD
Sorafenib—Dermatitis—Mycophenolic acid—psoriasis	7.53e-05	0.000393	CcSEcCtD
Sorafenib—Pain—Prednisolone—psoriasis	7.53e-05	0.000392	CcSEcCtD
Sorafenib—Haemorrhage—Methotrexate—psoriasis	7.53e-05	0.000392	CcSEcCtD
Sorafenib—Urticaria—Mycophenolate mofetil—psoriasis	7.5e-05	0.000391	CcSEcCtD
Sorafenib—Headache—Mycophenolic acid—psoriasis	7.49e-05	0.00039	CcSEcCtD
Sorafenib—Decreased appetite—Hydrocortisone—psoriasis	7.47e-05	0.000389	CcSEcCtD
Sorafenib—Body temperature increased—Mycophenolate mofetil—psoriasis	7.46e-05	0.000389	CcSEcCtD
Sorafenib—Abdominal pain—Mycophenolate mofetil—psoriasis	7.46e-05	0.000389	CcSEcCtD
Sorafenib—Urinary tract disorder—Methotrexate—psoriasis	7.43e-05	0.000387	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Hydrocortisone—psoriasis	7.42e-05	0.000387	CcSEcCtD
Sorafenib—Fatigue—Hydrocortisone—psoriasis	7.41e-05	0.000386	CcSEcCtD
Sorafenib—Urethral disorder—Methotrexate—psoriasis	7.38e-05	0.000384	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Triamcinolone—psoriasis	7.38e-05	0.000384	CcSEcCtD
Sorafenib—Pain—Hydrocortisone—psoriasis	7.35e-05	0.000383	CcSEcCtD
Sorafenib—Anaphylactic shock—Dexamethasone—psoriasis	7.35e-05	0.000383	CcSEcCtD
Sorafenib—Anaphylactic shock—Betamethasone—psoriasis	7.35e-05	0.000383	CcSEcCtD
Sorafenib—Infection—Betamethasone—psoriasis	7.3e-05	0.00038	CcSEcCtD
Sorafenib—Infection—Dexamethasone—psoriasis	7.3e-05	0.00038	CcSEcCtD
Sorafenib—Anaemia—Prednisone—psoriasis	7.24e-05	0.000378	CcSEcCtD
Sorafenib—Shock—Dexamethasone—psoriasis	7.23e-05	0.000377	CcSEcCtD
Sorafenib—Shock—Betamethasone—psoriasis	7.23e-05	0.000377	CcSEcCtD
Sorafenib—Dyspnoea—Triamcinolone—psoriasis	7.22e-05	0.000376	CcSEcCtD
Sorafenib—Nervous system disorder—Betamethasone—psoriasis	7.2e-05	0.000375	CcSEcCtD
Sorafenib—Nervous system disorder—Dexamethasone—psoriasis	7.2e-05	0.000375	CcSEcCtD
Sorafenib—Thrombocytopenia—Dexamethasone—psoriasis	7.19e-05	0.000375	CcSEcCtD
Sorafenib—Thrombocytopenia—Betamethasone—psoriasis	7.19e-05	0.000375	CcSEcCtD
Sorafenib—Angioedema—Prednisone—psoriasis	7.16e-05	0.000373	CcSEcCtD
Sorafenib—Hypersensitivity—Cyclosporine—psoriasis	7.13e-05	0.000371	CcSEcCtD
Sorafenib—Dyspepsia—Triamcinolone—psoriasis	7.13e-05	0.000371	CcSEcCtD
Sorafenib—Erythema multiforme—Methotrexate—psoriasis	7.12e-05	0.000371	CcSEcCtD
Sorafenib—Nausea—Mycophenolic acid—psoriasis	7.1e-05	0.00037	CcSEcCtD
Sorafenib—Gastrointestinal pain—Hydrocortisone—psoriasis	7.03e-05	0.000366	CcSEcCtD
Sorafenib—Syncope—Prednisone—psoriasis	7.03e-05	0.000366	CcSEcCtD
Sorafenib—Tinnitus—Methotrexate—psoriasis	7.02e-05	0.000366	CcSEcCtD
Sorafenib—Anorexia—Betamethasone—psoriasis	7e-05	0.000365	CcSEcCtD
Sorafenib—Anorexia—Dexamethasone—psoriasis	7e-05	0.000365	CcSEcCtD
Sorafenib—Urticaria—Prednisolone—psoriasis	6.99e-05	0.000364	CcSEcCtD
Sorafenib—Cardiac disorder—Methotrexate—psoriasis	6.98e-05	0.000364	CcSEcCtD
Sorafenib—Fatigue—Triamcinolone—psoriasis	6.98e-05	0.000364	CcSEcCtD
Sorafenib—Hypersensitivity—Mycophenolate mofetil—psoriasis	6.95e-05	0.000362	CcSEcCtD
Sorafenib—Asthenia—Cyclosporine—psoriasis	6.94e-05	0.000362	CcSEcCtD
Sorafenib—Pain—Triamcinolone—psoriasis	6.92e-05	0.000361	CcSEcCtD
Sorafenib—Loss of consciousness—Prednisone—psoriasis	6.89e-05	0.000359	CcSEcCtD
Sorafenib—Pruritus—Cyclosporine—psoriasis	6.84e-05	0.000357	CcSEcCtD
Sorafenib—Urticaria—Hydrocortisone—psoriasis	6.83e-05	0.000356	CcSEcCtD
Sorafenib—Angiopathy—Methotrexate—psoriasis	6.83e-05	0.000356	CcSEcCtD
Sorafenib—Immune system disorder—Methotrexate—psoriasis	6.8e-05	0.000354	CcSEcCtD
Sorafenib—Body temperature increased—Hydrocortisone—psoriasis	6.8e-05	0.000354	CcSEcCtD
Sorafenib—Abdominal pain—Hydrocortisone—psoriasis	6.8e-05	0.000354	CcSEcCtD
Sorafenib—Mediastinal disorder—Methotrexate—psoriasis	6.78e-05	0.000353	CcSEcCtD
Sorafenib—Asthenia—Mycophenolate mofetil—psoriasis	6.77e-05	0.000353	CcSEcCtD
Sorafenib—Hypertension—Prednisone—psoriasis	6.77e-05	0.000353	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Betamethasone—psoriasis	6.69e-05	0.000349	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Dexamethasone—psoriasis	6.69e-05	0.000349	CcSEcCtD
Sorafenib—Pruritus—Mycophenolate mofetil—psoriasis	6.68e-05	0.000348	CcSEcCtD
Sorafenib—Arthralgia—Prednisone—psoriasis	6.67e-05	0.000348	CcSEcCtD
Sorafenib—Myalgia—Prednisone—psoriasis	6.67e-05	0.000348	CcSEcCtD
Sorafenib—Alopecia—Methotrexate—psoriasis	6.65e-05	0.000347	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	6.63e-05	0.000345	CcSEcCtD
Sorafenib—Diarrhoea—Cyclosporine—psoriasis	6.62e-05	0.000345	CcSEcCtD
Sorafenib—Mental disorder—Methotrexate—psoriasis	6.59e-05	0.000344	CcSEcCtD
Sorafenib—Erythema—Methotrexate—psoriasis	6.55e-05	0.000341	CcSEcCtD
Sorafenib—Malnutrition—Methotrexate—psoriasis	6.55e-05	0.000341	CcSEcCtD
Sorafenib—Hypersensitivity—Prednisolone—psoriasis	6.49e-05	0.000338	CcSEcCtD
Sorafenib—Dyspepsia—Dexamethasone—psoriasis	6.47e-05	0.000337	CcSEcCtD
Sorafenib—Dyspepsia—Betamethasone—psoriasis	6.47e-05	0.000337	CcSEcCtD
Sorafenib—Diarrhoea—Mycophenolate mofetil—psoriasis	6.46e-05	0.000336	CcSEcCtD
Sorafenib—Urticaria—Triamcinolone—psoriasis	6.43e-05	0.000335	CcSEcCtD
Sorafenib—Dysgeusia—Methotrexate—psoriasis	6.41e-05	0.000334	CcSEcCtD
Sorafenib—Body temperature increased—Triamcinolone—psoriasis	6.4e-05	0.000334	CcSEcCtD
Sorafenib—Dizziness—Cyclosporine—psoriasis	6.4e-05	0.000333	CcSEcCtD
Sorafenib—Anaphylactic shock—Prednisone—psoriasis	6.4e-05	0.000333	CcSEcCtD
Sorafenib—Decreased appetite—Dexamethasone—psoriasis	6.39e-05	0.000333	CcSEcCtD
Sorafenib—Decreased appetite—Betamethasone—psoriasis	6.39e-05	0.000333	CcSEcCtD
Sorafenib—Infection—Prednisone—psoriasis	6.36e-05	0.000331	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Betamethasone—psoriasis	6.34e-05	0.00033	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Dexamethasone—psoriasis	6.34e-05	0.00033	CcSEcCtD
Sorafenib—Hypersensitivity—Hydrocortisone—psoriasis	6.33e-05	0.00033	CcSEcCtD
Sorafenib—Fatigue—Dexamethasone—psoriasis	6.33e-05	0.00033	CcSEcCtD
Sorafenib—Fatigue—Betamethasone—psoriasis	6.33e-05	0.00033	CcSEcCtD
Sorafenib—Shock—Prednisone—psoriasis	6.29e-05	0.000328	CcSEcCtD
Sorafenib—Pain—Dexamethasone—psoriasis	6.28e-05	0.000327	CcSEcCtD
Sorafenib—Pain—Betamethasone—psoriasis	6.28e-05	0.000327	CcSEcCtD
Sorafenib—Nervous system disorder—Prednisone—psoriasis	6.27e-05	0.000327	CcSEcCtD
Sorafenib—Dizziness—Mycophenolate mofetil—psoriasis	6.24e-05	0.000325	CcSEcCtD
Sorafenib—Skin disorder—Prednisone—psoriasis	6.21e-05	0.000324	CcSEcCtD
Sorafenib—Asthenia—Hydrocortisone—psoriasis	6.17e-05	0.000321	CcSEcCtD
Sorafenib—Vomiting—Cyclosporine—psoriasis	6.15e-05	0.000321	CcSEcCtD
Sorafenib—Rash—Cyclosporine—psoriasis	6.1e-05	0.000318	CcSEcCtD
Sorafenib—Anorexia—Prednisone—psoriasis	6.1e-05	0.000318	CcSEcCtD
Sorafenib—Dermatitis—Cyclosporine—psoriasis	6.09e-05	0.000318	CcSEcCtD
Sorafenib—Pruritus—Hydrocortisone—psoriasis	6.08e-05	0.000317	CcSEcCtD
Sorafenib—Headache—Cyclosporine—psoriasis	6.06e-05	0.000316	CcSEcCtD
Sorafenib—Anaemia—Methotrexate—psoriasis	6.05e-05	0.000316	CcSEcCtD
Sorafenib—Gastrointestinal pain—Dexamethasone—psoriasis	6.01e-05	0.000313	CcSEcCtD
Sorafenib—Gastrointestinal pain—Betamethasone—psoriasis	6.01e-05	0.000313	CcSEcCtD
Sorafenib—Vomiting—Mycophenolate mofetil—psoriasis	6e-05	0.000313	CcSEcCtD
Sorafenib—Hypersensitivity—Triamcinolone—psoriasis	5.96e-05	0.000311	CcSEcCtD
Sorafenib—Rash—Mycophenolate mofetil—psoriasis	5.95e-05	0.00031	CcSEcCtD
Sorafenib—Dermatitis—Mycophenolate mofetil—psoriasis	5.94e-05	0.00031	CcSEcCtD
Sorafenib—Headache—Mycophenolate mofetil—psoriasis	5.91e-05	0.000308	CcSEcCtD
Sorafenib—Diarrhoea—Hydrocortisone—psoriasis	5.88e-05	0.000307	CcSEcCtD
Sorafenib—Leukopenia—Methotrexate—psoriasis	5.86e-05	0.000306	CcSEcCtD
Sorafenib—Urticaria—Dexamethasone—psoriasis	5.84e-05	0.000304	CcSEcCtD
Sorafenib—Urticaria—Betamethasone—psoriasis	5.84e-05	0.000304	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Prednisone—psoriasis	5.83e-05	0.000304	CcSEcCtD
Sorafenib—Dizziness—Prednisolone—psoriasis	5.82e-05	0.000303	CcSEcCtD
Sorafenib—Asthenia—Triamcinolone—psoriasis	5.81e-05	0.000303	CcSEcCtD
Sorafenib—Abdominal pain—Betamethasone—psoriasis	5.81e-05	0.000303	CcSEcCtD
Sorafenib—Abdominal pain—Dexamethasone—psoriasis	5.81e-05	0.000303	CcSEcCtD
Sorafenib—Body temperature increased—Dexamethasone—psoriasis	5.81e-05	0.000303	CcSEcCtD
Sorafenib—Body temperature increased—Betamethasone—psoriasis	5.81e-05	0.000303	CcSEcCtD
Sorafenib—Nausea—Cyclosporine—psoriasis	5.75e-05	0.000299	CcSEcCtD
Sorafenib—Pruritus—Triamcinolone—psoriasis	5.73e-05	0.000298	CcSEcCtD
Sorafenib—Cough—Methotrexate—psoriasis	5.72e-05	0.000298	CcSEcCtD
Sorafenib—Dizziness—Hydrocortisone—psoriasis	5.69e-05	0.000296	CcSEcCtD
Sorafenib—Dyspepsia—Prednisone—psoriasis	5.63e-05	0.000293	CcSEcCtD
Sorafenib—Nausea—Mycophenolate mofetil—psoriasis	5.61e-05	0.000292	CcSEcCtD
Sorafenib—Arthralgia—Methotrexate—psoriasis	5.58e-05	0.000291	CcSEcCtD
Sorafenib—Myalgia—Methotrexate—psoriasis	5.58e-05	0.000291	CcSEcCtD
Sorafenib—Decreased appetite—Prednisone—psoriasis	5.56e-05	0.00029	CcSEcCtD
Sorafenib—Rash—Prednisolone—psoriasis	5.55e-05	0.000289	CcSEcCtD
Sorafenib—Dermatitis—Prednisolone—psoriasis	5.55e-05	0.000289	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	5.54e-05	0.000289	CcSEcCtD
Sorafenib—Fatigue—Prednisone—psoriasis	5.52e-05	0.000287	CcSEcCtD
Sorafenib—Headache—Prednisolone—psoriasis	5.52e-05	0.000287	CcSEcCtD
Sorafenib—Constipation—Prednisone—psoriasis	5.47e-05	0.000285	CcSEcCtD
Sorafenib—Vomiting—Hydrocortisone—psoriasis	5.47e-05	0.000285	CcSEcCtD
Sorafenib—Rash—Hydrocortisone—psoriasis	5.42e-05	0.000282	CcSEcCtD
Sorafenib—Dermatitis—Hydrocortisone—psoriasis	5.42e-05	0.000282	CcSEcCtD
Sorafenib—Headache—Hydrocortisone—psoriasis	5.39e-05	0.000281	CcSEcCtD
Sorafenib—Dizziness—Triamcinolone—psoriasis	5.35e-05	0.000279	CcSEcCtD
Sorafenib—Anaphylactic shock—Methotrexate—psoriasis	5.35e-05	0.000279	CcSEcCtD
Sorafenib—Infection—Methotrexate—psoriasis	5.31e-05	0.000277	CcSEcCtD
Sorafenib—Asthenia—Betamethasone—psoriasis	5.27e-05	0.000275	CcSEcCtD
Sorafenib—Asthenia—Dexamethasone—psoriasis	5.27e-05	0.000275	CcSEcCtD
Sorafenib—Nervous system disorder—Methotrexate—psoriasis	5.24e-05	0.000273	CcSEcCtD
Sorafenib—Thrombocytopenia—Methotrexate—psoriasis	5.23e-05	0.000273	CcSEcCtD
Sorafenib—Gastrointestinal pain—Prednisone—psoriasis	5.23e-05	0.000273	CcSEcCtD
Sorafenib—Nausea—Prednisolone—psoriasis	5.23e-05	0.000272	CcSEcCtD
Sorafenib—Pruritus—Betamethasone—psoriasis	5.2e-05	0.000271	CcSEcCtD
Sorafenib—Pruritus—Dexamethasone—psoriasis	5.2e-05	0.000271	CcSEcCtD
Sorafenib—Skin disorder—Methotrexate—psoriasis	5.19e-05	0.000271	CcSEcCtD
Sorafenib—Vomiting—Triamcinolone—psoriasis	5.15e-05	0.000268	CcSEcCtD
Sorafenib—Nausea—Hydrocortisone—psoriasis	5.11e-05	0.000266	CcSEcCtD
Sorafenib—Rash—Triamcinolone—psoriasis	5.1e-05	0.000266	CcSEcCtD
Sorafenib—Dermatitis—Triamcinolone—psoriasis	5.1e-05	0.000266	CcSEcCtD
Sorafenib—Anorexia—Methotrexate—psoriasis	5.1e-05	0.000266	CcSEcCtD
Sorafenib—Urticaria—Prednisone—psoriasis	5.08e-05	0.000265	CcSEcCtD
Sorafenib—Headache—Triamcinolone—psoriasis	5.07e-05	0.000264	CcSEcCtD
Sorafenib—Abdominal pain—Prednisone—psoriasis	5.06e-05	0.000264	CcSEcCtD
Sorafenib—Body temperature increased—Prednisone—psoriasis	5.06e-05	0.000264	CcSEcCtD
Sorafenib—Diarrhoea—Dexamethasone—psoriasis	5.03e-05	0.000262	CcSEcCtD
Sorafenib—Diarrhoea—Betamethasone—psoriasis	5.03e-05	0.000262	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Methotrexate—psoriasis	4.87e-05	0.000254	CcSEcCtD
Sorafenib—Dizziness—Betamethasone—psoriasis	4.86e-05	0.000253	CcSEcCtD
Sorafenib—Dizziness—Dexamethasone—psoriasis	4.86e-05	0.000253	CcSEcCtD
Sorafenib—Nausea—Triamcinolone—psoriasis	4.81e-05	0.000251	CcSEcCtD
Sorafenib—Dyspnoea—Methotrexate—psoriasis	4.77e-05	0.000248	CcSEcCtD
Sorafenib—Hypersensitivity—Prednisone—psoriasis	4.71e-05	0.000246	CcSEcCtD
Sorafenib—Dyspepsia—Methotrexate—psoriasis	4.71e-05	0.000245	CcSEcCtD
Sorafenib—Vomiting—Dexamethasone—psoriasis	4.67e-05	0.000243	CcSEcCtD
Sorafenib—Vomiting—Betamethasone—psoriasis	4.67e-05	0.000243	CcSEcCtD
Sorafenib—Decreased appetite—Methotrexate—psoriasis	4.65e-05	0.000242	CcSEcCtD
Sorafenib—Rash—Betamethasone—psoriasis	4.63e-05	0.000241	CcSEcCtD
Sorafenib—Rash—Dexamethasone—psoriasis	4.63e-05	0.000241	CcSEcCtD
Sorafenib—Dermatitis—Dexamethasone—psoriasis	4.63e-05	0.000241	CcSEcCtD
Sorafenib—Dermatitis—Betamethasone—psoriasis	4.63e-05	0.000241	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Methotrexate—psoriasis	4.62e-05	0.000241	CcSEcCtD
Sorafenib—Fatigue—Methotrexate—psoriasis	4.61e-05	0.00024	CcSEcCtD
Sorafenib—Headache—Dexamethasone—psoriasis	4.6e-05	0.00024	CcSEcCtD
Sorafenib—Headache—Betamethasone—psoriasis	4.6e-05	0.00024	CcSEcCtD
Sorafenib—Asthenia—Prednisone—psoriasis	4.59e-05	0.000239	CcSEcCtD
Sorafenib—Pain—Methotrexate—psoriasis	4.57e-05	0.000238	CcSEcCtD
Sorafenib—Pruritus—Prednisone—psoriasis	4.53e-05	0.000236	CcSEcCtD
Sorafenib—Diarrhoea—Prednisone—psoriasis	4.38e-05	0.000228	CcSEcCtD
Sorafenib—Gastrointestinal pain—Methotrexate—psoriasis	4.37e-05	0.000228	CcSEcCtD
Sorafenib—Nausea—Dexamethasone—psoriasis	4.36e-05	0.000227	CcSEcCtD
Sorafenib—Nausea—Betamethasone—psoriasis	4.36e-05	0.000227	CcSEcCtD
Sorafenib—Urticaria—Methotrexate—psoriasis	4.25e-05	0.000221	CcSEcCtD
Sorafenib—Dizziness—Prednisone—psoriasis	4.23e-05	0.00022	CcSEcCtD
Sorafenib—Abdominal pain—Methotrexate—psoriasis	4.23e-05	0.00022	CcSEcCtD
Sorafenib—Body temperature increased—Methotrexate—psoriasis	4.23e-05	0.00022	CcSEcCtD
Sorafenib—Vomiting—Prednisone—psoriasis	4.07e-05	0.000212	CcSEcCtD
Sorafenib—Rash—Prednisone—psoriasis	4.03e-05	0.00021	CcSEcCtD
Sorafenib—Dermatitis—Prednisone—psoriasis	4.03e-05	0.00021	CcSEcCtD
Sorafenib—Headache—Prednisone—psoriasis	4.01e-05	0.000209	CcSEcCtD
Sorafenib—Hypersensitivity—Methotrexate—psoriasis	3.94e-05	0.000205	CcSEcCtD
Sorafenib—Asthenia—Methotrexate—psoriasis	3.84e-05	0.0002	CcSEcCtD
Sorafenib—Nausea—Prednisone—psoriasis	3.8e-05	0.000198	CcSEcCtD
Sorafenib—Pruritus—Methotrexate—psoriasis	3.78e-05	0.000197	CcSEcCtD
Sorafenib—Diarrhoea—Methotrexate—psoriasis	3.66e-05	0.000191	CcSEcCtD
Sorafenib—Dizziness—Methotrexate—psoriasis	3.54e-05	0.000184	CcSEcCtD
Sorafenib—Vomiting—Methotrexate—psoriasis	3.4e-05	0.000177	CcSEcCtD
Sorafenib—Rash—Methotrexate—psoriasis	3.37e-05	0.000176	CcSEcCtD
Sorafenib—Dermatitis—Methotrexate—psoriasis	3.37e-05	0.000176	CcSEcCtD
Sorafenib—Headache—Methotrexate—psoriasis	3.35e-05	0.000175	CcSEcCtD
Sorafenib—Nausea—Methotrexate—psoriasis	3.18e-05	0.000165	CcSEcCtD
Sorafenib—FGFR1—Immune System—CD4—psoriasis	7.27e-06	5.13e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—NOS2—psoriasis	7.26e-06	5.12e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—CAT—psoriasis	7.26e-06	5.12e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CD4—psoriasis	7.25e-06	5.11e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TYK2—psoriasis	7.25e-06	5.11e-05	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—CXCL8—psoriasis	7.23e-06	5.1e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—TYK2—psoriasis	7.22e-06	5.1e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—LEP—psoriasis	7.18e-06	5.06e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—APOE—psoriasis	7.18e-06	5.06e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—LEP—psoriasis	7.18e-06	5.06e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—APOE—psoriasis	7.18e-06	5.06e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—IL6—psoriasis	7.11e-06	5.02e-05	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—IL6—psoriasis	7.11e-06	5.02e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.08e-06	4.99e-05	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—IL6—psoriasis	7.07e-06	4.99e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—CD4—psoriasis	7.07e-06	4.99e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TYK2—psoriasis	7.06e-06	4.98e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—TYK2—psoriasis	7.05e-06	4.97e-05	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—IL6—psoriasis	6.96e-06	4.91e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.91e-06	4.87e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—JUN—psoriasis	6.86e-06	4.84e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—JUN—psoriasis	6.86e-06	4.84e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—LEP—psoriasis	6.81e-06	4.8e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—APOE—psoriasis	6.81e-06	4.8e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—LEP—psoriasis	6.79e-06	4.79e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—APOE—psoriasis	6.79e-06	4.79e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IFNG—psoriasis	6.76e-06	4.77e-05	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—IL6—psoriasis	6.75e-06	4.76e-05	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	6.75e-06	4.76e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—IL6—psoriasis	6.73e-06	4.75e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—CD4—psoriasis	6.71e-06	4.73e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—APOE—psoriasis	6.71e-06	4.73e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—APOE—psoriasis	6.71e-06	4.73e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—CD4—psoriasis	6.7e-06	4.72e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NFKBIA—psoriasis	6.69e-06	4.72e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NFKBIA—psoriasis	6.69e-06	4.72e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—TYK2—psoriasis	6.67e-06	4.7e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—NFKB1—psoriasis	6.6e-06	4.66e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—NFKB1—psoriasis	6.6e-06	4.66e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CARM1—psoriasis	6.59e-06	4.65e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—STAT3—psoriasis	6.58e-06	4.64e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—CXCL8—psoriasis	6.57e-06	4.63e-05	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—TP53—psoriasis	6.56e-06	4.63e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CD4—psoriasis	6.53e-06	4.61e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—JUN—psoriasis	6.51e-06	4.59e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—JUN—psoriasis	6.49e-06	4.58e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.45e-06	4.55e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—TYK2—psoriasis	6.44e-06	4.54e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CARM1—psoriasis	6.44e-06	4.54e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SOCS1—psoriasis	6.38e-06	4.5e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NFKBIA—psoriasis	6.35e-06	4.48e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NFKBIA—psoriasis	6.33e-06	4.46e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CXCL8—psoriasis	6.31e-06	4.45e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—TP53—psoriasis	6.3e-06	4.44e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—NFKB1—psoriasis	6.26e-06	4.42e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—NFKB1—psoriasis	6.25e-06	4.41e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.16e-06	4.35e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CXCL8—psoriasis	6.15e-06	4.34e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—CXCL8—psoriasis	6.14e-06	4.33e-05	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—IL6—psoriasis	6.12e-06	4.32e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—LEP—psoriasis	6.12e-06	4.32e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—APOE—psoriasis	6.12e-06	4.32e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—TYK2—psoriasis	6.08e-06	4.29e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TYK2—psoriasis	6.07e-06	4.28e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—IL6—psoriasis	6.07e-06	4.28e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CARM1—psoriasis	6.07e-06	4.28e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—CD4—psoriasis	6.03e-06	4.25e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IFNG—psoriasis	6.03e-06	4.25e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TYK2—psoriasis	6.02e-06	4.24e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—STAT3—psoriasis	6.02e-06	4.24e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CARM1—psoriasis	6.01e-06	4.24e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—TYK2—psoriasis	5.94e-06	4.19e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—STAT3—psoriasis	5.93e-06	4.18e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—STAT3—psoriasis	5.93e-06	4.18e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—JUN—psoriasis	5.87e-06	4.14e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—JUN—psoriasis	5.85e-06	4.12e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PPARG—psoriasis	5.84e-06	4.12e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PPARG—psoriasis	5.84e-06	4.12e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—APOE—psoriasis	5.84e-06	4.12e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—LEP—psoriasis	5.84e-06	4.12e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—CXCL8—psoriasis	5.83e-06	4.11e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CD4—psoriasis	5.82e-06	4.11e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—IL6—psoriasis	5.8e-06	4.09e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—IL6—psoriasis	5.77e-06	4.07e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—JUN—psoriasis	5.72e-06	4.03e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NFKBIA—psoriasis	5.7e-06	4.02e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—APOE—psoriasis	5.69e-06	4.01e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—TP53—psoriasis	5.67e-06	4e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—NFKB1—psoriasis	5.65e-06	3.98e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—APOE—psoriasis	5.64e-06	3.98e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—STAT3—psoriasis	5.63e-06	3.97e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—NFKB1—psoriasis	5.63e-06	3.97e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.62e-06	3.96e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—STAT3—psoriasis	5.61e-06	3.96e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.51e-06	3.89e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—NFKB1—psoriasis	5.5e-06	3.88e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TYK2—psoriasis	5.48e-06	3.86e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TYK2—psoriasis	5.48e-06	3.86e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—STAT3—psoriasis	5.48e-06	3.86e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—APOE—psoriasis	5.45e-06	3.85e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—LEP—psoriasis	5.45e-06	3.85e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NFKBIA—psoriasis	5.44e-06	3.84e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—IL6—psoriasis	5.41e-06	3.81e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—CD4—psoriasis	5.38e-06	3.79e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CAT—psoriasis	5.37e-06	3.79e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—CXCL8—psoriasis	5.3e-06	3.74e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CXCL8—psoriasis	5.29e-06	3.73e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CAT—psoriasis	5.25e-06	3.7e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CXCL8—psoriasis	5.24e-06	3.7e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—JUN—psoriasis	5.21e-06	3.68e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TYK2—psoriasis	5.2e-06	3.67e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—STAT3—psoriasis	5.2e-06	3.67e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—IL6—psoriasis	5.19e-06	3.66e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TYK2—psoriasis	5.18e-06	3.66e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—STAT3—psoriasis	5.18e-06	3.66e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CARM1—psoriasis	5.14e-06	3.62e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—VEGFA—psoriasis	5.13e-06	3.62e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NFKBIA—psoriasis	5.08e-06	3.58e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—STAT3—psoriasis	5.08e-06	3.58e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—STAT3—psoriasis	5.06e-06	3.57e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—NFKB1—psoriasis	5.02e-06	3.54e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—VEGFA—psoriasis	5e-06	3.52e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PPARG—psoriasis	4.96e-06	3.5e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—STAT3—psoriasis	4.95e-06	3.49e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—JUN—psoriasis	4.92e-06	3.47e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PPARG—psoriasis	4.91e-06	3.46e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—JUN—psoriasis	4.87e-06	3.44e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.8e-06	3.39e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CXCL8—psoriasis	4.77e-06	3.36e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CXCL8—psoriasis	4.77e-06	3.36e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—NFKB1—psoriasis	4.73e-06	3.34e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—APOE—psoriasis	4.71e-06	3.32e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—LEP—psoriasis	4.71e-06	3.32e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—NFKB1—psoriasis	4.69e-06	3.31e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TYK2—psoriasis	4.67e-06	3.29e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—STAT3—psoriasis	4.67e-06	3.29e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL6—psoriasis	4.59e-06	3.24e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CAT—psoriasis	4.54e-06	3.21e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CXCL8—psoriasis	4.53e-06	3.19e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CXCL8—psoriasis	4.51e-06	3.18e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—STAT3—psoriasis	4.51e-06	3.18e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TYK2—psoriasis	4.45e-06	3.14e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—JUN—psoriasis	4.43e-06	3.13e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—JUN—psoriasis	4.43e-06	3.13e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NFKBIA—psoriasis	4.39e-06	3.09e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—VEGFA—psoriasis	4.3e-06	3.03e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NFKB1—psoriasis	4.27e-06	3.01e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NFKB1—psoriasis	4.27e-06	3.01e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—VEGFA—psoriasis	4.26e-06	3e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—STAT3—psoriasis	4.25e-06	3e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—STAT3—psoriasis	4.21e-06	2.97e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—JUN—psoriasis	4.21e-06	2.97e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—IL6—psoriasis	4.2e-06	2.96e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—JUN—psoriasis	4.2e-06	2.96e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—APOE—psoriasis	4.17e-06	2.94e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TYK2—psoriasis	4.16e-06	2.94e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—STAT3—psoriasis	4.16e-06	2.94e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL6—psoriasis	4.14e-06	2.92e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL6—psoriasis	4.14e-06	2.92e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—APOE—psoriasis	4.08e-06	2.88e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CXCL8—psoriasis	4.07e-06	2.87e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CAT—psoriasis	4.06e-06	2.86e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NFKB1—psoriasis	4.05e-06	2.86e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NFKB1—psoriasis	4.04e-06	2.85e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CARM1—psoriasis	3.97e-06	2.8e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CAT—psoriasis	3.96e-06	2.79e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL6—psoriasis	3.93e-06	2.77e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL6—psoriasis	3.92e-06	2.77e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CXCL8—psoriasis	3.88e-06	2.74e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—VEGFA—psoriasis	3.87e-06	2.73e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—VEGFA—psoriasis	3.87e-06	2.73e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—psoriasis	3.87e-06	2.73e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—STAT3—psoriasis	3.84e-06	2.7e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—STAT3—psoriasis	3.84e-06	2.7e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—IL6—psoriasis	3.83e-06	2.7e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—JUN—psoriasis	3.78e-06	2.67e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—psoriasis	3.77e-06	2.66e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CAT—psoriasis	3.73e-06	2.63e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CAT—psoriasis	3.7e-06	2.61e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL6—psoriasis	3.69e-06	2.6e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—VEGFA—psoriasis	3.68e-06	2.59e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—VEGFA—psoriasis	3.67e-06	2.59e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—STAT3—psoriasis	3.64e-06	2.57e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NFKB1—psoriasis	3.64e-06	2.57e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PPARG—psoriasis	3.63e-06	2.56e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—IL6—psoriasis	3.63e-06	2.56e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—STAT3—psoriasis	3.63e-06	2.56e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CXCL8—psoriasis	3.62e-06	2.56e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—IL6—psoriasis	3.62e-06	2.55e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—JUN—psoriasis	3.61e-06	2.54e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TYK2—psoriasis	3.59e-06	2.53e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PPARG—psoriasis	3.55e-06	2.5e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL6—psoriasis	3.55e-06	2.5e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL6—psoriasis	3.53e-06	2.49e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—APOE—psoriasis	3.53e-06	2.49e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NFKB1—psoriasis	3.47e-06	2.45e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL6—psoriasis	3.45e-06	2.44e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL6—psoriasis	3.45e-06	2.43e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—JUN—psoriasis	3.37e-06	2.38e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VEGFA—psoriasis	3.3e-06	2.33e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—STAT3—psoriasis	3.27e-06	2.31e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—psoriasis	3.26e-06	2.3e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—psoriasis	3.25e-06	2.29e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NFKB1—psoriasis	3.24e-06	2.29e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—psoriasis	3.22e-06	2.27e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CAT—psoriasis	3.16e-06	2.23e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—APOE—psoriasis	3.15e-06	2.22e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VEGFA—psoriasis	3.15e-06	2.22e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—psoriasis	3.15e-06	2.22e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CXCL8—psoriasis	3.13e-06	2.21e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—STAT3—psoriasis	3.12e-06	2.2e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—APOE—psoriasis	3.08e-06	2.17e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PPARG—psoriasis	3.08e-06	2.17e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—psoriasis	2.98e-06	2.1e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—psoriasis	2.97e-06	2.1e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VEGFA—psoriasis	2.94e-06	2.08e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—psoriasis	2.94e-06	2.08e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—psoriasis	2.93e-06	2.06e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—psoriasis	2.93e-06	2.06e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—STAT3—psoriasis	2.91e-06	2.06e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—JUN—psoriasis	2.91e-06	2.05e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—psoriasis	2.91e-06	2.05e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—APOE—psoriasis	2.9e-06	2.04e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—APOE—psoriasis	2.87e-06	2.03e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NFKB1—psoriasis	2.8e-06	1.97e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—psoriasis	2.78e-06	1.96e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—psoriasis	2.77e-06	1.95e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARG—psoriasis	2.75e-06	1.94e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARG—psoriasis	2.68e-06	1.89e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—psoriasis	2.68e-06	1.89e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—psoriasis	2.68e-06	1.89e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—psoriasis	2.54e-06	1.79e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VEGFA—psoriasis	2.54e-06	1.79e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—psoriasis	2.54e-06	1.79e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARG—psoriasis	2.52e-06	1.78e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—STAT3—psoriasis	2.52e-06	1.77e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARG—psoriasis	2.5e-06	1.77e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—psoriasis	2.5e-06	1.76e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—APOE—psoriasis	2.46e-06	1.73e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CAT—psoriasis	2.44e-06	1.72e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—psoriasis	2.38e-06	1.68e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—psoriasis	2.28e-06	1.61e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—psoriasis	2.22e-06	1.57e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—psoriasis	2.18e-06	1.54e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARG—psoriasis	2.14e-06	1.51e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—psoriasis	2.04e-06	1.44e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—psoriasis	1.92e-06	1.35e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOE—psoriasis	1.9e-06	1.34e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—psoriasis	1.76e-06	1.24e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARG—psoriasis	1.65e-06	1.16e-05	CbGpPWpGaD
